Literature DB >> 521827

Measles antibodies and histocompatibility types in multiple sclerosis.

M E Fewster, F R Ames, M C Botha.   

Abstract

Measles antibody titres and HLA antigens were determined in 71 White and 11 Coloured multiple sclerosis (MS) patients and 71 White and 11 Coloured age and sex-matched controls. Measles antibody titres were determined by the hemagglutination inhibition test and HLA antigens were determined serologically by a micro-lymphocytotoxicity test. Measles antibody titres were significantly higher in MS than in control cases and this was true for both female and male patients. No association was observed between the HLA antigens, especially HLA-A3 or HLA-B7 and measles antibody titres in the sera of MS patients or controls.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 521827     DOI: 10.1016/0022-510x(79)90070-4

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  4 in total

1.  Multiple sclerosis in the Orkney and Shetland Islands. II: The search for an exogenous aetiology.

Authors:  D C Poskanzer; J L Sheridan; L B Prenney; A M Walker
Journal:  J Epidemiol Community Health       Date:  1980-12       Impact factor: 3.710

2.  Multiple sclerosis in the Orkney and Shetland Islands. V: The effect on viral titres of histocompatibility determinants.

Authors:  D C Poskanzer; J L Sever; P I Terasaki; L B Prenney; J L Sheridan; M S Park
Journal:  J Epidemiol Community Health       Date:  1980-12       Impact factor: 3.710

3.  Viral antibody titers, immunogenetic markers, and their interrelations in multiple sclerosis patients and controls.

Authors:  A Alpérovitch; C Berr; A Cambon-Thomsen; J Puel; J M Dugoujon; J B Ruidavets; M Clanet
Journal:  Hum Immunol       Date:  1991-06       Impact factor: 2.850

Review 4.  Abnormalities of serum and plasma components in patients with multiple sclerosis.

Authors:  H C Ford
Journal:  Clin Biochem       Date:  1985-02       Impact factor: 3.281

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.